- Patent Title: Pharmaceutical composition comprising Pistacia weinmannifolia extract, fraction of same or compound separated from same for preventing or treating chronic obstructive pulmonary disease (COPD)
-
Application No.: US15304316Application Date: 2015-04-17
-
Publication No.: US10751378B2Publication Date: 2020-08-25
- Inventor: Sei Ryang Oh , Kyung Seop Ahn , Seung Hyung Kim , In Sik Shin , Hang Jin , Jung Hee Kim , Hyung Won Ryu , Wan Yi Li , Sang Woo Lee , Joong Ku Lee , Sang Ho Choi
- Applicant: Korea Research Institute of Bioscience and Biotechnology
- Applicant Address: KR
- Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
- Current Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
- Current Assignee Address: KR
- Agency: Lathrop GPM LLP
- Agent Andrew T. Wilkins; Michael J. Spellberg
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@4af3173
- International Application: PCT/KR2015/003881 WO 20150417
- International Announcement: WO2015/160219 WO 20151022
- Main IPC: A61K36/22
- IPC: A61K36/22 ; A23L33/105 ; A61K9/00 ; A61K31/12 ; A61P11/00

Abstract:
The present invention relates to a composition for suppressing chronic obstructive pulmonary disease (COPD) comprising a Pistacia weinmannifolia extract, a fraction thereof, or a compound isolated therefrom and, more particularly, to a pharmaceutical composition for preventing or treating COPD comprising a Pistacia weinmannifolia extract, a fraction thereof, or a compound isolated therefrom; a food composition for preventing or improving COPD, and the compound isolated therefrom. The composition comprising a Pistacia weinmannifolia extract, a fraction thereof, or a compound isolated therefrom, according to the present invention, is not toxic, suppresses the invasion of inflammatory cells into the bronchial tube of a COPD-induced animal model, and effectively suppresses the expression of CXCL-1, TNF-α, or MIP-2. In addition, due to the use of a safety-proven herbal drug as a raw material, the composition of the present invention can resolve various side-effects of existing therapeutic agents for COPD, chronic obstructive bronchitis, chronic bronchiolitis, emphysema, multiple sclerosis, and acute and chronic inflammation, and thus can be effectively used as a composition for preventing, treating and remedying COPD.
Public/Granted literature
Information query